Trial Outcomes & Findings for A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes (NCT NCT07030868)
NCT ID: NCT07030868
Last Updated: 2026-08-31
Results Overview
Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.
TERMINATED
PHASE2
1 participants
Baseline, Week 32
2026-08-31
Participant Flow
The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected, and no analyses could be performed.
Participant milestones
| Measure |
LY3549492 or Placebo (Randomised, Not Treated)
One participant was randomized to one of the planned study interventions (LY3549492 low dose, LY3549492 high dose with fast titration, LY3549492 high dose with slow titration, or placebo).
The study was terminated after enrollment of the participant. The participant did not receive any study treatment and did not undergo any post-baseline efficacy or safety assessments prior to study termination.
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
Received at Least One Dose of Study Drug
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
Baseline characteristics by cohort
| Measure |
LY3549492 or Placebo (Randomised, Not Treated)
n=1 Participants
One participant was randomized to one of the planned study interventions (LY3549492 low dose, LY3549492 high dose with fast titration, LY3549492 high dose with slow titration, or placebo).
The study was terminated after enrollment of the participant. The participant did not receive any study treatment and did not undergo any post-baseline efficacy or safety assessments prior to study termination.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=14 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=14 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=14 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=14 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=14 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=14 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=14 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=14 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=14 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=14 Participants
|
PRIMARY outcome
Timeframe: Baseline, Week 32Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, Week 32Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and absolute change from baseline was to be calculated.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, Week 32Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Percentage of participants who achieved at least 5% reduction in body weight from baseline to Week 32.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, Week 32Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Percentage of participants who achieved at least 10% reduction in body weight from baseline to Week 32.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, Week 32Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Change from baseline in hemoglobin A1c (HbA1c) at Week 32. HbA1c was intended to be measured as a percentage and reflects average blood glucose levels over approximately 3 months.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).Population: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.
Average plasma concentration of LY3549492. Pharmacokinetic samples were intended to be collected at multiple timepoints, including pre-dose and post-dose intervals, to evaluate the pharmacokinetic profile of LY3549492 over time.
Outcome measures
Outcome data not reported
Adverse Events
LY3549492 or Placebo (Randomised, Not Treated)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60